Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05164536 · ClinicalTrials.gov registry record · Phase 1
Plasma P-tau2017 and Quantitative Amyloid PET Imaging
A Phase 1 study, sponsored by Invicro.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT05164536: Completed Phase 1 study, sponsored by Invicro.
NCT05164536 is a Phase 1 study that has completed, run by Invicro. The registered enrollment target is 140 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05164536, a Phase 1 study, has completed, sponsored by Invicro.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
The overall goal of this protocol is to compare amyloid burden assessed by amyloid PET to plasma P-tau217 levels.
Primary Outcome
Amyloid PET imaging will be used to measure regional brain amyloid deposition in each subject.
Interventions
- DRUG Amyvid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2022-11-08 |
| Phase | Phase 1 |
What the finished NCT05164536 record still lists
NCT05164536 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher).
The record links to 0 conditions, and to 1 intervention - of which Amyvid is the first listed.
NCT05164536 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05164536 about?
NCT05164536 is a clinical study titled "Plasma P-tau2017 and Quantitative Amyloid PET Imaging". The overall goal of this protocol is to compare amyloid burden assessed by amyloid PET to plasma P-tau217 levels.
What is the current status of trial NCT05164536?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2021-08-27. Estimated completion is 2022-11-08.
What interventions are being tested in trial NCT05164536?
The interventions under investigation include: Amyvid (DRUG).
Who is sponsoring clinical trial NCT05164536?
This trial is sponsored by Invicro, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05164536's enrollment target sits among peer trials
140 402nd of 2000 higher than 1,583 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI